The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive ...

The Ministry of Health (MoH) has introduced the pneumococcal conjugate vaccine (PCV) into Brunei Darussalam’s Expanded Programme on Immunisation, effective FeB 1 as part of efforts to protect infants ...

Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data ---- Company Expects to Announce VAX-31 ...

Drug major Merck & Co. (MRK) announced Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use or ...

Merck , known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the ...

There are about 100 different types (referred to as serotypes) of pneumococcal bacteria, which can affect adults differently than children. Pneumococcal disease can be invasive or non-invasive.

Merck receives positive EU CHMP opinion for Capvaxive for pneumococcal vaccination in adults: Rahway, New Jersey Monday, February 3, 2025, 12:00 Hrs [IST] Merck, known as MSD outs ...

Therefore, the introduction of the Pneumococcal Conjugate Vaccine, PCV into the Brunei Darussalam National Expansion Immunisation Programme will provide an opportunity to protect infants and young ...

SAN CARLOS, Calif. - Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company valued at $10.78 billion, has announced the commencement of the final stage of its Phase 2 study for VAX-31, a ...

The global viral vaccines market size was valued at USD 45.20 billion in 2024 and is projected to reach from USD 49 billion ...